SCHEMBL3170477

SCHEMBL3170477

CC(C)C[C@H](NC(=O)[C@H](CCCNC(=N)N[N+](=O)[O-])NC(=O)c1ccccn1)B(O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 14/20 0.59
LONP1 P36776 9/20 0.51
PSMB1 P20618 6/20 0.48
PSMB8 P28062 6/20 0.48
PSMB9 P28065 6/20 0.48
PSMB10 P40306 6/20 0.48
PSMB2 P49721 6/20 0.48
PSMB11 A5LHX3 5/20 0.48
PSMA7 O14818 5/20 0.48
PSMA1 P25786 5/20 0.48
PSMA2 P25787 5/20 0.48
PSMA3 P25788 5/20 0.48
PSMA4 P25789 5/20 0.48
PSMA5 P28066 5/20 0.48
PSMB4 P28070 5/20 0.48
PSMB6 P28072 5/20 0.48
PSMB3 P49720 5/20 0.48
PSMA6 P60900 5/20 0.48
PSMA8 Q8TAA3 5/20 0.48
PSMB7 Q99436 5/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15291250 0.89 PSMB5 (0.64) PSMB5LONP1PSMB1PSMB8PSMB9
SCHEMBL3164160 0.89 LONP1 (0.68) PSMB5LONP1PSMB1PSMB8PSMB9
SCHEMBL12754442 0.87 PSMB5 (0.56) PSMB5LONP1PSMB1PSMB2CLPP
SCHEMBL3160855 0.86 PSMB5 (0.47) PSMB5LONP1PSMB1PSMB8PSMB9
SCHEMBL1326103 0.86 GRIA1 (0.43) PSMB5HDAC1
SCHEMBL12754514 0.85 CLPP (0.51) PSMB5LONP1PSMB1PSMB2CLPP
SCHEMBL3173295 0.85 LONP1 (0.49) PSMB5LONP1PSMB1PSMB8PSMB9
SCHEMBL1326097 0.83 CTSK (0.38) PSMB5HDAC1
SCHEMBL12754437 0.83 PSMB5 (0.44) PSMB5PSMB1PSMB2CLPP
SCHEMBL3162447 0.83 PSMB5 (0.44) PSMB5PSMB1PSMB2CLPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1660507-B9 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-03-24 EP claimed
EP-1660507-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2009-08-05 EP claimed
US-9233115-B2 Proteasome inhibitors and methods of using the same MILLENNIUM PHARMACEUTICALS INC. (US) 2016-01-12 US disclosed
US-20140088042-A1 Proteasome Inhibitors And Methods Of Using The Same CEPHALON, INC. (US) 2014-03-27 US disclosed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 US disclosed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 US disclosed
US-7576206-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME PSMB11, PSMB5, PSMB6 PSMB5 2/4885LONP1 279/4885PSMB1 4/4885
US-20140088042-A1 Proteasome Inhibitors And Methods Of Using The Same PSMB11, PSMB5, PSMB6 PSMB5 2/4885LONP1 279/4885PSMB1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.